LLLu Li

Lu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lu Li has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Vassilios Papadopoulos

    Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA

    7 shared publications
  • Wai-Yee Chan

    School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

    7 shared publications
  • Chantal Sottas

    Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy University of Southern California Los Angeles California USA

    3 shared publications
  • Garett Cheung

    Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy University of Southern California Los Angeles California USA

    3 shared publications
  • Hoi-Hung Cheung

    School of Biomedical Sciences Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China

    3 shared publications
  • Shen Gu

    School of Biomedical Sciences Faculty of Medicine The Chinese University of Hong Kong (CUHK) Hong Kong SAR China

    3 shared publications

Latest Publications

  • Open Access

    Mitochondrial dynamics, Leydig cell function, and age‐related testosterone deficiency

    by Samuel Garza, Liting Chen, Melanie Galano, Garett Cheung, Chantal Sottas, Lu Li, Yuchang Li, Barry R. Zirkin, Vassilios Papadopoulos

    The mitochondrial translocator protein (18 kDa; TSPO) is a high‐affinity cholesterol‐binding protein that is an integral component of the cholesterol trafficking scaffold responsible for determining the rate of cholesterol import into the mitochondria for steroid biosynthesis. Previous studies have shown that TSPO declines in aging Leydig cells (LCs) and that its decline is associated with depressed circulating testosterone levels in aging rats. However, TSPO's role in the mechanistic decline in LC function is not fully understood. To address the role of TSPO depletion in LC function, we first examined mitochondrial quality in Tspo knockout mouse tumor MA‐10 nG1 LCs compared to wild‐type MA‐10 cells. Tspo deletion caused a disruption in mitochondrial function and membrane dynamics. Increasing mitochondrial fusion via treatment with the mitochondrial fusion promoter M1 or by optic atrophy 1 (OPA1) overexpression resulted in the restoration of mitochondrial function and mitochondrial morphology as well as in steroid formation in TSPO‐depleted nG1 LCs. LCs isolated from aged rats form less testosterone than LCs isolated from young rats. Treatment of aging LCs with M1 improved mitochondrial function and increased androgen formation, suggesting that aging LC dysfunction may stem from compromised mitochondrial dynamics caused by the age‐dependent LC TSPO decline. These results, taken together, suggest that maintaining or enhancing mitochondrial fusion may provide therapeutic strategies to maintain or restore testosterone levels with aging.


  • Abstract 693: ASKG843, a bifunctional fusion protein of PD1/TGF-βRII, demonstrates potent in vitro/in vivo activities, and excellent pharmacokinetic properties in non-human primates (NHPs) with good safety profiles

    by Liqin Liu, Shiwen Zhang, Kurt Shanebeck, Mouzhong Xu, Yunxia Yuan, Ming Li, Lu Li, Ray Chuang, Yong Wen, Yuefeng Lu, et al.

    Introduction: Antibodies targeting the immune checkpoint PD1/PD-L1 are emerging as effective cancer immunotherapies, but most cancers fail to respond to these as single agents. Tumor cells and the tumor microenvironment (TME) frequently express transforming growth factor-β (TGF-β) to either drive immune cell dysfunction in the microenvironment or to exclude immune cell infiltration into tumors. Concurrently targeting the immunosuppressive/immune-excluding TGF-β pathway represents a rational and promising strategy to enhance PD1/PD-L1-based immunotherapies. ASKG843 is a bifunctional molecule designed to simultaneously block PD1/PD-L1 pathway and disable all three TGF-β isoforms in the TME. Here we report the functional evaluation of ASKG843 in vitro, anti-tumor activity in vivo, pharmacokinetic (PK) and pharmacodynamic (PD) properties in cynomolgus monkeys as well as its safety profiles following 5-repeat weekly dosing in NHPs. Methods: ASKG843 was constructed comprising αhPD1 Ab with the C-terminus of the heavy chain fused to the ECD of human TGF-βRII via flexible linkers. Bispecific binding properties were evaluated by Fortebio and bispecific ELISA. Respective signaling blockade for PD1 and TGF-β were assessed using either PD1/NFAT-luciferase reporter system or TGF-β/SMAD-luciferase reporter cell line. The anti-tumor activity of ASKG843 was determined in human PBMC-engrafted NSG mice-bearing A375 xenografts. The PK/PD and safety profiles of ASKG843 were assessed in NHPs. Results: Fortebio and bispecific ELISA analyses demonstrated the ability of ASKG843 to simultaneously bind both human PD1 and TGF-β1-3. ASKG843 not only dose-dependently blocked PD1/PD-L1 inhibitory axis with similar potency to parental αPD1 Ab in PD1 bioassay, but also thwarted TGF-β canonical signaling with IC50 =14.7 ng/mL in TGF-β bioassay. In human PBMC-reconstituted A375 xenograft model ASKG843 promoted strong anti-tumor response with efficacy comparable to the reference molecule (PD-L1/TGF-βRII) at the same dose/dosing frequency. In cynomolgus monkeys ASKG843 demonstrated superior PK to PD-L1/TGF-βRII reference molecule resulting in sustained depletion of TGF-β in peripheral blood for at least 10 days following single injection at 5 mg/kg dose, and no toxicity-related sign observed which contrasted with the reference molecule. Most encouragingly ASKG843 maintained very good safety profiles in cynomolgus monkeys following multiple injections at dose up to 100 mg/kg. Conclusions: ASKG843 demonstrated potent bi-functional activities in vitro and in vivo endowed by its design. Superior PK to the reference molecule yet maintaining better safety profiles in NHPs support further development of ASKG843 as an effective immunotherapeutic candidate. Citation Format: Liqin Liu, Shiwen Zhang, Kurt Shanebeck, Mouzhong Xu, Yunxia Yuan, Ming Li, Lu Li, Ray Chuang, Yong Wen, Yuefeng Lu, Jeff Lu. ASKG843, a bifunctional fusion protein of PD1/TGF-βRII, demonstrates potent in vitro/in vivo activities, and excellent pharmacokinetic properties in non-human primates (NHPs) with good safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 693.


  • Advances in stem cell research for the treatment of primary hypogonadism

    by Lu Li, Vassilios Papadopoulos

    In Leydig cell dysfunction, cells respond weakly to stimulation by pituitary luteinizing hormone, and, therefore, produce less testosterone, leading to primary hypogonadism. The most widely used treatment for primary hypogonadism is testosterone replacement therapy (TRT). However, TRT causes infertility and has been associated with other adverse effects, such as causing erythrocytosis and gynaecomastia, worsening obstructive sleep apnoea and increasing cardiovascular morbidity and mortality risks. Stem-cell-based therapy that re-establishes testosterone-producing cell lineages in the body has, therefore, become a promising prospect for treating primary hypogonadism. Over the past two decades, substantial advances have been made in the identification of Leydig cell sources for use in transplantation surgery, including the artificial induction of Leydig-like cells from different types of stem cells, for example, stem Leydig cells, mesenchymal stem cells, and pluripotent stem cells (PSCs). PSC-derived Leydig-like cells have already provided a powerful in vitro model to study the molecular mechanisms underlying Leydig cell differentiation and could be used to treat men with primary hypogonadism in a more specific and personalized approach.


  • Open Access

    Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease

    by Yuchang Li, Liting Chen, Lu Li, Chantal Sottas, Stephanie K. Petrillo, Anthoula Lazaris, Peter Metrakos, Hangyu Wu, Yuji Ishida, Takeshi Saito, et al.


  • Open Access

    Role of Constitutive STAR in Leydig Cells

    by Melanie Galano, Yuchang Li, Lu Li, Chantal Sottas, Vassilios Papadopoulos

    Leydig cells contain significant amounts of constitutively produced steroidogenic acute regulatory protein (STAR; STARD1). Hormone-induced STAR plays an essential role in inducing the transfer of cholesterol into the mitochondria for hormone-dependent steroidogenesis. STAR acts at the outer mitochondrial membrane, where it interacts with a protein complex, which includes the translocator protein (TSPO). Mutations in STAR cause lipoid congenital adrenal hyperplasia (lipoid CAH), a disorder characterized by severe defects in adrenal and gonadal steroid production; in Leydig cells, the defects are seen mainly after the onset of hormone-dependent androgen formation. The function of constitutive STAR in Leydig cells is unknown. We generated STAR knockout (KO) MA-10 mouse tumor Leydig cells and showed that STAR KO cells failed to form progesterone in response to dibutyryl-cAMP and to TSPO drug ligands, but not to 22(R)-hydroxycholesterol, which is a membrane-permeable intermediate of the CYP11A1 reaction. Electron microscopy of STAR KO cells revealed that the number and size of lipid droplets were similar to those in wild-type (WT) MA-10 cells. However, the density of lipid droplets in STAR KO cells was drastically different than that seen in WT cells. We isolated the lipid droplets and analyzed their content by liquid chromatography–mass spectrometry. There was a significant increase in cholesteryl ester and phosphatidylcholine content in STAR KO cell lipid droplets, but the most abundant increase was in the amount of diacylglycerol (DAG); DAG 38:1 was the predominantly affected species. Lastly, we identified genes involved in DAG signaling and lipid metabolism which were differentially expressed between WT MA-10 and STAR KO cells. These results suggest that constitutive STAR in Leydig cells is involved in DAG accumulation in lipid droplets, in addition to cholesterol transport. The former event may affect cell functions mediated by DAG signaling.


  • Open Access

    Why does COVID‐19 kill more elderly men than women? Is there a role for testosterone?

    by Vassilios Papadopoulos, Lu Li, Mary Samplaski

    Background: Recent epidemiological data indicate that there may be a gender predisposition to COVID‐19, with men predisposed to being most severely affected, and older men accounting for most deaths.Objectives: Provide a review of the research literature, propose hypotheses, and therapies based on the potential link between testosterone (T) and COVID‐19 induced mortality in elderly men.Materials and Methods: A search of publications in academic electronic databases, and government and public health organization web sites on T, aging, inflammation, severe acute respiratory syndrome (SARS) due to coronavirus (CoV) 2 (SARS‐CoV‐2) infection, and COVID‐19 disease state and outcomes was performed.Results: The link between T, the immune system, and male aging is well‐established, as is the progressive decline in T levels with aging. In women, T levels drop before menopause and variably increase with advanced age. Elevated IL‐6 is a characteristic biomarker of patients infected with COVID‐19 and has been linked to the development of the acute respiratory distress syndrome (ARDS). Thus far, half of the admitted COVID‐19 patients developed ARDS, half of these patients died, and elderly male patients have been more likely to develop ARDS and die. Low T is associated with ARDS. These data suggest that low T levels may exacerbate the severity of COVID‐19 infection in elderly men. It may also stand to reason that normal T levels may offer some protection against COVID‐19. SARS‐CoV‐2 binds to the angiotensin‐converting enzyme 2, present in high levels in the testis.Conclusion: At present, it is not known whether low T levels in aging hypogonadal males create a permissive environment for severe responses to COVID‐19 infection or if the virus inhibits androgen formation. Given the preponderance of COVID‐19 related mortality in elderly males, additional testing for gonadal function and treatment with T may be merited.


  • Directing differentiation of human induced pluripotent stem cells toward androgen-producing Leydig cells rather than adrenal cells

    by Lu Li, Yuchang Li, Chantal Sottas, Martine Culty, Jinjiang Fan, Yiman Hu, Garett Cheung, Héctor E. Chemes, Vassilios Papadopoulos

    Reduced serum testosterone (T), or hypogonadism, affects millions of men and is associated with many pathologies, including infertility, cardiovascular diseases, metabolic syndrome, and decreased libido and sexual function. Administering T-replacement therapy (TRT) reverses many of the symptoms associated with low T levels. However, TRT is linked to side effects such as infertility and increased risk of prostate cancer and cardiovascular diseases. Thus, there is a need to obtain T-producing cells that could be used to treat hypogonadism via transplantation and reestablishment of T-producing cell lineages in the body. T is synthesized by Leydig cells (LCs), proposed to derive from mesenchymal cells of mesonephric origin. Although mesenchymal cells have been successfully induced into LCs, the limited source and possible trauma to donors hinders their application to clinical therapies. Alternatively, human induced pluripotent stem cells (hiPSCs), which are expandable in culture and have the potential to differentiate into all somatic cell types, have become the emerging source of autologous cell therapies. We have successfully induced the differentiation of hiPSCs into either human Leydig-like (hLLCs) or adrenal-like cells (hALCs) using chemically defined culture conditions. Factors critical for the development of LCs were added to both culture systems. hLLCs expressed all steroidogenic genes and proteins important for T biosynthesis, synthesized T rather than cortisol, secreted steroid hormones in response to dibutyryl-cAMP and 22(R)-hydroxycholesterol, and displayed ultrastructural features resembling LCs. By contrast, hALCs synthesized cortisol rather than T. The success in generating hiPSC-derived hLLCs with broad human LC (hLC) features supports the potential for hiPSC-based hLC regeneration. Significance Our results suggest that both androgen- and cortisol-producing human Leydig and adrenal cells can be induced from human induced pluripotent stem cells. This bidirectional approach offers insights into the events specifying different steroidogenic cell populations sharing developmental origins. More importantly, our study provides a way to generate possible transplantation materials for clinical therapies. Human Leydig-like cells could also be useful for in vitro studies of testicular development and pathologies of testis-relevant diseases, and for the discovery of new drugs inducing androgen formation for hypogonadism treatment.


  • Open Access

    Analysis of spatiotemporal specificity of small RNAs regulating hPSC differentiation and beyond

    by Lu Li, Jin Feng Li, Dan Dan Cao, Vassilios Papadopoulos, Wai Yee Chan

    We present a quantitative analysis of small RNA dynamics during the transition from hPSCs to the three germ layer lineages to identify spatiotemporal-specific small RNAs that may be involved in hPSC differentiation. To determine the degree of spatiotemporal specificity, we utilized two algorithms, namely normalized maximum timepoint specificity index (NMTSI) and across-tissue specificity index (ASI). NMTSI could identify spatiotemporal-specific small RNAs that go up or down at just one timepoint in a specific lineage. ASI could identify spatiotemporal-specific small RNAs that maintain high expression from intermediate timepoints to the terminal timepoint in a specific lineage. Beyond analyzing single small RNAs, we also quantified the spatiotemporal-specificity of microRNA families and observed their differential expression patterns in certain lineages. To clarify the regulatory effects of group miRNAs on cellular events during lineage differentiation, we performed a gene ontology (GO) analysis on the downstream targets of synergistically up-and downregulated microRNAs. To provide an integrated interface for researchers to access and browse our analysis results, we designed a web-based tool at https://keyminer.pythonanywhere.com/km/ .

  • Open Access

    Comparison of multi-lineage differentiation of hiPSCs reveals novel miRNAs that regulate lineage specification

    by Lu Li, Kai-Kei Miu, Shen Gu, Hoi-Hung Cheung, Wai-Yee Chan

    MicroRNAs (miRNAs) are known to be crucial players in governing the differentiation of human induced pluripotent stem cells (hiPSCs). Despite their utter importance, identifying key lineage specifiers among the myriads of expressed miRNAs remains challenging. We believe that the current practice in mining miRNA specifiers via delineating dynamic fold-changes only is inadequate. Our study, therefore, provides evidence to pronounce “lineage specificity” as another important attribute to qualify for these lineage specifiers. Adopted hiPSCs were differentiated into representative lineages (hepatic, nephric and neuronal) over all three germ layers whilst the depicted miRNA expression changes compiled into an integrated atlas. We demonstrated inter-lineage analysis shall aid in the identification of key miRNAs with lineage-specificity, while these shortlisted candidates were collectively known as “lineage-specific miRNAs”. Subsequently, we followed through the fold-changes along differentiation via computational analysis to identify miR-192 and miR-372-3p, respectively, as representative candidate key miRNAs for the hepatic and nephric lineages. Indeed, functional characterization validated that miR-192 and miR-372-3p regulate lineage differentiation via modulation of the expressions of lineage-specific genes. In summary, our presented miRNA atlas is a resourceful ore for the mining of key miRNAs responsible for lineage specification.


  • Open Access

    MicroRNA profiling during directed differentiation of cortical interneurons from human‐induced pluripotent stem cells

    by Jiajie Tu, Dandan Cao, Lu Li, Hoi‐Hung Cheung, Wai‐Yee Chan

    Induced pluripotent stem cells (iPSCs) are useful for modeling neuron development and related diseases. Cortical interneurons are essential players in neuropsychiatric diseases such as autism. miRNAs are a class of pivotal regulators in neural differentiation. Using a previously established model of cortical interneuron differentiation from human embryonic stem cells, we profiled miRNAs involved in differentiation from human iPSCs. A number of miRNAs were modulated in the differentiation process. This study captured the temporal in vitro neurogenesis from iPSCs to mature cortical interneurons. The specific miRNAs identified at each stage of differentiation are of potential use for drug discovery and prospective clinical applications.